Huffman’s argument came in response to a June 24 ruling, by Franklin County Common Pleas Judge Jaiza N. Page, that Ohio’s ...
Gilead Sciences GILD recently announced that it has exercised its combined option to exclusively license Assembly Biosciences’ ASMB herpes simplex virus (HSV) helicase-primase inhibitor programs. The ...
– Weekly Oral Helicase-Primase Inhibitor Programs' Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years – Genital herpes, caused by HSV, is a chronic ...
Gilead Sciences, Inc. (NASDAQ: GILD) and Assembly Biosciences, Inc. (NASDAQ: ASMB) announced on Monday that Gilead has exercised its combined option to exclusively license Assembly Bio’s herpes ...
– Weekly Oral Helicase-Primase Inhibitor Programs' Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years – “At Gilead, we develop novel antiviral ...
FOSTER CITY, Calif. - Gilead Sciences, Inc. (NASDAQ:GILD) has exercised its option to exclusively license Assembly Biosciences, Inc.’s (NASDAQ:ASMB) herpes simplex virus (HSV) helicase-primase ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has exercised its combined option to exclusively license Assembly Bio’s herpes simplex virus ...
FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has exercised its ...
– Weekly Oral Helicase-Primase Inhibitor Programs' Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years – Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback